{"title":"KNK437 Suppresses the Growth of Non-Small Cell Lung Cancer Cells by Targeting Heat Shock Factor 1","authors":"Lili Wu, Jieni Feng, Hualong Lin, Peirui Chen","doi":"10.1002/ddr.70141","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Heat shock factor 1 (HSF1) has emerged as a promising therapeutic target in various solid tumors. However, its specific role in non-small cell lung cancer (NSCLC) and the potential efficacy of HSF1 inhibitors in this context remain largely unexplored. The current data showed that HSF1 is overexpressed in NSCLC cells and is positively associated with poorer survival outcomes in NSCLC patients. Moreover, the HSF1 inhibitor KNK437 markedly suppresses NSCLC cell proliferation and induces dose-dependent cell cycle arrest and apoptosis. In addition, KNK437 significantly alters the expression of HSF1 and its downstream target genes in HSF1-overexpressing NSCLC cells, while HSF1 knockdown markedly attenuates the anti-proliferative effects of KNK437, indicating that its therapeutic efficacy is largely mediated through HSF1 inhibition. Finally, molecular docking simulations revealed that KNK437 engages in hydrophobic interactions and forms two critical hydrogen bonds with HSF1, potentially underpinning its inhibitory activity. Collectively, these findings support HSF1 as a compelling molecular target for NSCLC treatment and highlight KNK437 as a promising therapeutic candidate.</p>\n </div>","PeriodicalId":11291,"journal":{"name":"Drug Development Research","volume":"86 5","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development Research","FirstCategoryId":"3","ListUrlMain":"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/ddr.70141","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Heat shock factor 1 (HSF1) has emerged as a promising therapeutic target in various solid tumors. However, its specific role in non-small cell lung cancer (NSCLC) and the potential efficacy of HSF1 inhibitors in this context remain largely unexplored. The current data showed that HSF1 is overexpressed in NSCLC cells and is positively associated with poorer survival outcomes in NSCLC patients. Moreover, the HSF1 inhibitor KNK437 markedly suppresses NSCLC cell proliferation and induces dose-dependent cell cycle arrest and apoptosis. In addition, KNK437 significantly alters the expression of HSF1 and its downstream target genes in HSF1-overexpressing NSCLC cells, while HSF1 knockdown markedly attenuates the anti-proliferative effects of KNK437, indicating that its therapeutic efficacy is largely mediated through HSF1 inhibition. Finally, molecular docking simulations revealed that KNK437 engages in hydrophobic interactions and forms two critical hydrogen bonds with HSF1, potentially underpinning its inhibitory activity. Collectively, these findings support HSF1 as a compelling molecular target for NSCLC treatment and highlight KNK437 as a promising therapeutic candidate.
期刊介绍:
Drug Development Research focuses on research topics related to the discovery and development of new therapeutic entities. The journal publishes original research articles on medicinal chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discovery and development process. In addition to full-length articles, Drug Development Research publishes Brief Reports on important and timely new research findings, as well as in-depth review articles. The journal also features periodic special thematic issues devoted to specific compound classes, new technologies, and broad aspects of drug discovery and development.